



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/938,628	08/27/2001	Patrick G. Morand	06478.1459-00000	1173

7590

01/04/2006

Aventis Behring LLC  
1020 First Avenue  
P O Box 61501  
King of Prussia, PA 61501

EXAMINER

KOPPIKAR, VIVEK D

ART UNIT

PAPER NUMBER

3626

DATE MAILED: 01/04/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/938,628

Applicant(s)

MORAND ET AL.

Examiner

Vivek D. Koppikar

Art Unit

3626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 8/27/01.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-68 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-68 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 27 August 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date 12/14/01 ~~12/14/00~~
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date: \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

**DETAILED ACTION**

***Status of the Application***

1. Claims 1-68 have been examined in this application. The Information Disclosure Statement (IDS) statement filed on December 14, 2001 and April 10, 2002 have been acknowledged.

***Claim Rejections - 35 USC § 103***

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

3. Claims 1, 4, 6-9, 11-14, 16, 21-24, 28-30, 33-36, 38, 42-44 and 66-67 are rejected under 35 U.S.C. 103(a) as being unpatentable over US Patent Number 5,991,729 in view of US Patent Number 6,368,797 to Schappert.

(A) As per claim 1, Barry teaches a method for identifying a research subject (Barry: Abstract), comprising:

obtaining medical data from a subject (Barry: Col. 4, Ln. 8-15);  
associating an identifier for said subject with said medical data in at least a first database (Barry: Col. 4, Ln. 26-31);  
associating the identifier for said subject with the name and contact information of said subject (Barry: Col. 4, Ln. 33-48);  
extracting an identifier from the first database, wherein said identifier is associated with a subject matching the identified criteria (Barry: Col. 5, Ln. 53-62); and

Art Unit: 3626

matching the identifier from the first database with the name and contact information in order to identify the research subject (Barry: Col. 5, Ln. 53-62).

Barry does not teach the step of identifying criteria for selecting a research subject; however, this feature is well known in the art as evidenced by Schappert (Col. 12, Ln. 43-52). At the time of the invention it would have been obvious to one of ordinary skill in the art to have modified the method in Barry with the aforementioned feature from Schappert with the motivation of providing a powerful prognostic tool for the treatment of a disease as recited in Schappert (Col. 12, Ln. 27-33).

(B) As per claim 4, in the combined method of Barry in view of Schappert the method of claim 1 is repeated for each member (Barry: Col. 4, Ln. 32-52).

(C) As per claims 6-7, the combined method of Barry in view of Schappert teaches that the medical data comprise a medical history and a family history (Barry: Col. 4, Ln. 26-48).

(D) As per claim 8, in the combined method of Barry in view of Schappert the medical data comprise clinical chemistry test results (Barry: Col. 4, Ln. 7-12).

(E) As per claim 9, in the combined method of Barry in view of Schappert the medical data comprise pharmacogenomic or genomic data (Barry: Col. 4, Ln. 7-24).

(F) As per claim 11, in the combined method of Barry in view of Schappert the criteria includes medical history information (Barry: Col. 4, Ln. 26-48).

(G) As per claim 12, in the combined method of Barry in view of Schappert the criteria include family history information (Barry: Col. 4, Ln. 26-48).

(H) As per claim 13, in the combined method of Barry in view of Schappert the criteria include clinical chemistry test results (Barry: Col. 4, Ln. 7-12).

Art Unit: 3626

(I) As per claim 14, in the combined method of Barry in view of Schappert the criteria include pharmacogenomic or genomic information (Barry: Col. 4, Ln. 7-24).

(J) As per claim 16, in the combined method of Barry in view of Schappert the first database is a computerized database (Barry: Col. 4, Ln. 26-47).

(K) As per claims 21-23, in the combined method of Barry in view of Schappert the database is computerized, and the network is either an intranet or the Internet (Barry: Col. 4, Ln. 56-Col. 5, Ln. 6).

(L) As per claim 24, Barry teaches a method for identifying a research subject in a group of donors from at least one collection establishment, comprising:

a. obtaining a biological sample and medical data from a donor (Barry: Col. 4, Ln. 9-12);

b. associating an identifier for said donor with said biological sample and medical data in at least a first database (Barry: Col. 4, Ln. 32-48).

c. associating the identifier for said blood donor with the name and contact information of said donor (Barry: Col. 4, Ln. 32-48)

f. matching the identifier from the first database with the name and contact information in order to identify a research subject (Col. 4, Ln. 32-48).

Barry does not teach the step d. of identifying criteria for selecting a research subject nor does Barry teach the step e. of extracting an identifier from the first database, wherein said identifier is associated with a donor matching the identified criteria; however, this feature is well known in the art as evidenced by Schappert (Col. 12, Ln. 43-52). At the time of the invention it would have been obvious to one of ordinary skill in the art to have modified the method in Barry

Art Unit: 3626

with the aforementioned feature from Schappert with the motivation of providing a powerful prognostic tool for the treatment of a disease as recited in Schappert (Col. 12, Ln. 27-33).

(M) As per claim 28, in the combined method of Barry in view of Schappert the medical data comprises medical history data (Barry: Col. 4, Ln. 26-48).

(N) As per claim 29, in the combined method of Barry in view of Schappert the medical data comprise a family history (Barry: Col. 4, Ln. 26-48).

(O) As per claim 30, in the combined method of Barry in view of Schappert the medical data comprise clinical test results (Barry: Col. 4, Ln. 7-12).

(P) As per claim 33, in the combined method of Barry in view of Schappert the criteria include medical history information (Barry: Col. 4, Ln. 26-48).

(Q) As per claim 34, in the combined method of Barry in view of Schappert the criteria include family history information (Barry: Col. 4, Ln. 26-48).

(R) As per claim 35, in the combined method of Barry in view of Schappert the criteria include clinical test results (Barry: Col. 4, Ln. 9-12).

(S) As per claim 36, in the combined method of Barry in view of Schappert the criteria include pharmacogenomic or genomic information (Barry: Col. 4, Ln. 7-24).

(T) As per claim 38, in the combined method of Barry in view of Schappert the first database is a computerized database (Barry: Col. 4, Ln. 26-29 and Ln. 48-52).

(U) As per claims 42-44, in the combined method of Barry in view of Schappert the database is computerized, and the network is either an intranet or the Internet (Barry: Col. 4, Ln. 56-Col. 5, Ln. 6).

Art Unit: 3626

(V) As per claim 66, the combined method of Barry in view of Schappert teaches the step of identifying the research subject according to claim 1 according to the selected criteria (Schappert: Col. 12, Ln. 43-52); and also teaches the step of contacting the research subject for recruiting the research subject for a clinical study (Barry: Col. 4, Ln. 26-47). The motivation for combining these two teaching is stated above in the paragraph setting forth the rejection of Claim 1.

(W) As per claim 67, the combined method of Barry in view of Schappert teaches the step of identifying the research subject according to claim 1 according to the selected criteria (Schappert: Col. 12, Ln. 43-52); and also teaches the step of contacting the research subject for recruiting the research subject for a clinical study (Barry: Col. 4, Ln. 26-47). The motivation for combining these two teaching is stated above in the paragraph setting forth the rejection of Claim 24.

4. Claims 2 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Barry in view of Schappert as applied to Claims 1 and 24, above, respectively.

(A) As per claims 2 and 25, the combined method of Barry in view of Schappert does not teach the step of obtaining informed consent from the subject, wherein the informed consent permits the medical data to be used to identify the subject as a potential research subject, however, the examiner takes Official Notice that this feature is well known in the field of patient and medical records. At the time of the invention, it would have been obvious for one of ordinary skill in the art to have obtained informed consent from a patient before using that patient's medical records with the motivation of protecting the patient's right to privacy.

5. Claim 3 is rejected under 35 U.S.C. as being unpatentable over Barry in view of Schappert as applied to Claim 1, and in further view of US Patent Number 5,626,144 to Tacklind.

(A) As per claim 3, the combined method of Barry in view of Schappert does not teach or suggest that medical data are obtained from the subject and associated with the identifier for the subject in at least a first database longitudinally, however, this feature is well known in the art as evidenced by Tacklind (Col. 5, Ln. 55-63 and Col. 6, Ln. 5-13). At the time of the invention, it would have been obvious for one of ordinary skill in the art to have modified the combined method of Barry in view of Schappert with the aforementioned feature from Tacklind with the motivation of obtaining a means of pairing a patient with a remote sensor and a subscription pairing a device ID with a care provider, as recited in Tacklind (Col. 6, Ln. 5-14).

6. Claim 46 is rejected under 35 U.S.C. 103(a) as being unpatentable over Barry in view of US Patent Number 5,626,144 to Tacklind.

(A) As per claim 46, Barry teaches a plurality of biological samples collected from at least one subject (Barry: Abstract), wherein each sample is associated with an identifier linking said biological sample to at least one of medical data, genomic data, pharmacological data, and proteomic data in at least a first database (Barry: Col. 4, Ln. 7-47). Barry does not teach that the biological samples are collected and stored longitudinally, however, this feature is well known in the art as evidenced by Tacklind (Col. 5, Ln. 55-63 and Col. 6, Ln. 5-13). At the time of the invention, it would have been obvious for one of ordinary skill in the art to have modified the invention of Barry with the aforementioned feature from Tacklind with the motivation of

Art Unit: 3626

obtaining a means of pairing a patient with a remote sensor and a subscription pairing a device ID with a care provider, as recited in Tacklind (Col. 6, Ln. 5-14).

(B) As per claim 47, in the combined invention of Barry in view of Tacklind the samples are blood and blood cells (Barry: Col. 4, Ln. 7-12).

7. Claim 48 is rejected under 35 U.S.C. 103(a) as being unpatentable over Barry in view of Tacklind.

(A) As per claim 48, Barry teaches a plurality of biological samples collected from at least one donor (Barry: Abstract), wherein each sample is collected at a collection establishment and associated with an identifier linking the donor and the biological sample to at least one of medical data, genomic data, pharmacogenomic data, and proteomic data in at least a first database (Barry: Col. 4, Ln. 7-47). Barry does not teach that the biological samples are collected and stored longitudinally; however, this feature is well known in the art as evidenced by Tacklind (Col. 5, Ln. 55-63 and Col. 6, Ln. 5-13). At the time of the invention, it would have been obvious for one of ordinary skill in the art to have modified the invention of Barry with the aforementioned feature from Tacklind with the motivation of obtaining a means of pairing a patient with a remote sensor and a subscription pairing a device ID with a care provider, as recited in Tacklind (Col. 6, Ln. 5-14).

8. Claim 49 is rejected under 35 U.S.C. 103(a) as being unpatentable over Barry in view of Tacklind.

(A) As per claim 49, Barry teaches a method for creating a database (Barry: Abstract), the method comprising:

- a. collecting a biological sample from at least one subject (Barry: Col. 4, Ln. 7-12);

- b. collecting medical data from at least one subject (Barry: Col. 4, Ln. 7-12);
- c. deriving proteomic information and genomic information from the sample (Barry: Col. 4, Ln. 22-26);
- d. storing the sample in a location from which the sample can be recovered (Barry: Col. 4, Ln. 21-26);
- e. associating the medical data, the proteomic information, and the genomic information with an identifier that can be used to locate the sample (Barry: Col. 4, Ln. 33-47).

Barry does not teach or suggest the step of f. of performing steps a to e on the same subject longitudinally; and wherein steps b to d may be performed in any order; however, this feature is well known in the art as evidenced by Tacklind (Col. 5, Ln. 55-63 and Col. 6, Ln. 5-13). At the time of the invention, it would have been obvious for one of ordinary skill in the art to have modified the method of Barry with the aforementioned feature from Tacklind with the motivation of obtaining a means of pairing a patient with a remote sensor and a subscription pairing a device ID with a care provider, as recited in Tacklind (Col. 6, Ln. 5-14).

(B) As per claim 50, in the combined method of Barry in view of Tacklind the steps a to f are performed on multiple subjects (patients) (Barry: Col. 5, Ln. 28-47).

(C) As per claim 51, in the combined method of Barry in view of Tacklind the biological sample is blood (Barry: Col. 4, Ln. 7-12).

(D) As per claim 52, in the combined method of Barry in view of Tacklind the samples are collected from at least one collection establishment (Barry: Col. 4, Ln. 7-12).

(E) As per claim 53, in the combined method of Barry in view of Tacklind the medical data comprises chemistry test formation (Barry: Col. 4, Ln. 16-26).

(F) As per claim 59, in the combined method of Barry in view of Tacklind the medical data comprises family histories from the subjects (Barry: Col. 4, Ln. 33-47).

(G) As per claim 60, in the combined method of Barry in view of Tacklind the medical data comprises demographic information from the subjects (Barry: Col. 4, Ln. 33-47).

(H) As per claim 61, in the combined method of Barry in view of Tacklind the medical data comprises at least one of the medical data, the genomic information, the proteomic information, and the location for the sample is associated with an identifier for the subject that can be used to retrieve the name and contact information for the subject (Barry: Col. 5, Ln. 19-27).

9. Claims 5, 27 and 68 are rejected under 35 U.S.C. 103(a) as being unpatentable over Barry in view of Schappert as applied to Claims 1 and 24, above, respectively, and in further view of US Patent Number 5,915,240 to Karpf.

(A) As per claims 5, 27 and 68, the combined method of Barry in view of Schappert does not teach or suggest that the subject (patient) is a deferred donor, however, this feature is well known in the art as evidenced by Karpf (Col. 14, Ln. 27-34). At the time of the invention, it would have been obvious to one of ordinary skill in the art to have modified the combined method of Barry in view of Schappert with the aforementioned feature from Karpf with the motivation of providing a means to providing descriptions of the patient, as recited in Karpf (Col. 14, Ln. 31-33).

10. Claims 9-10, 14-15, 31-32, and 36-37 are rejected as being unpatentable over Barry in view of Schappert as applied to Claims 1 and 24, above, respectively, and in further view of US Patent Number 6,730,477 to Sun.

Art Unit: 3626

(A) As per claims 9-10, 14-15, 31-32, and 36-37 the combined method of Barry in view of Schappert does not teach that the medical data comprises pharmacogenomic, genomic or proteomic data, however, this feature is well known in the art as evidenced by Sun (Col. 6, Ln. 61-Col. 7, Ln. 8 and Col. 7, Ln. 10-23 and Col. 8, Ln. 31-49). At the time of the invention, it would have been obvious to one of ordinary skill in the art to have included these types of medical data in the combined method of Barry in view of Schappert with the motivation of obtaining an enhanced means of detecting, diagnosing and monitoring various diseases, as recited in Sun (Col. 3, Ln. 63-Col. 4, Ln. 4).

11. Claims 55-58 and 62-65 are rejected as being unpatentable over Barry in view of Tacklind, as applied to Claim 49, above and in further view of Sun.

(A) As per claims 55-58 and 62-65, the combined method of Barry in view of Tacklind does not teach that the medical data comprises pharmacogenomic, genomic or proteomic data as well as the other recited types of data in these claims, however, this feature is well known in the art as evidenced by Sun (Col. 6, Ln. 61-Col. 7, Ln. 8 and Col. 7, Ln. 10-23 and Col. 8, Ln. 31-49). At the time of the invention, it would have been obvious to one of ordinary skill in the art to have included these types of medical data in the combined method of Barry in view of Schappert with the motivation of obtaining an enhanced means of detecting, diagnosing and monitoring various diseases, as recited in Sun (Col. 3, Ln. 63-Col. 4, Ln. 4).

12. Claims 17-20 and 39-42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Barry in view of Schappert, as applied to Claims 1 and 24, above, respectively.

(A) As per claims 17-20 and 39-42, the combined method of Barry in view of Schappert does not teach or suggest a second computerized database stored on a separate computer and a

Art Unit: 3626

network firewall separating the first and second computers, however, the examiner take Official Notice that this is a feature well known in the field of informational technology and computer networks. At the time of the invention, it would have been obvious for one of ordinary skill in the art to have included the above mentioned features with the motivation of providing a backup, archival data source so that vital patient data would not be destroyed if one of the computers was damaged.

*Conclusion*

13. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

US Patent Application Publication 2002/0019706 to Rienhoff.

US Patent Application Publication 2002/0032581 to Reitberg.

US Patent Application Publication 2002/0099570 to Knight.

14. Any inquire concerning this communication or earlier communications from the examiner should be directed to Vivek Koppikar, whose telephone number is (571) 272-5109. The examiner can normally be reached from Monday to Friday between 8 AM and 4:30 PM.


If any attempt to reach the examiner by telephone is unsuccessful, the examiner's supervisor, Joseph Thomas, can be reached at (571) 272-6776. The fax telephone number for this group is (703) 305-7687 (for official communications including After Final communications labeled "Box AF").

Another resource that is available to applicants is the Patent Application Information Retrieval (PAIR). Information regarding the status of an application can be obtained from the (PAIR) system. Status information for published applications may be obtained from either


Art Unit: 3626

Private PAIR or Public PAX. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, please feel free to contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sincerely,

  
Vivek Koppikar

12/8/2005

  
JOSEPH THOMAS  
SUPERVISOR  
TECHNOLOGY CENTER